Important developments in dementia: biomarkers & clinical trials

Philip Tipton, MD, Mayo Clinic, Jacksonville, FL, outlines the most important developments in dementia from the past years. The development of biomarkers has been one of the most significant advances in the dementia field. Since most of the diseases causing dementia are neurodegenerative, it is critical to have biomarkers to inform on disease progression and severity. The second biggest advance in recent years has been the development and approval of novel drugs. In June 2021, the FDA granted accelerated approval to aducanumab - a monoclonal antibody with a high affinity for neurotoxic oligomeric amyloid-beta - for the treatment of early Alzheimer's disease. Although the approval of aducanumab was controversial, it was also a landmark moment as it was the first time that a treatment that may provide disease-modifying effects was available for patients with Alzheimer's disease. Three other monoclonal antibodies are currently being evaluated in clinical trials: donanemab, gantenerumab, and lecanemab. Data from those clinical trials are expected in the following months and will provide more insights into anti-amyloid antibodies in Alzheimer's disease and potentially change the treatment landscape. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Be the first to comment